obesity

10 Most Unhealthy Fast-Food Items on America's Menu

America is getting heavier and less healthy every year, and our increasing consumption of fast food is at least partially to blame. 24/7 Wall St. examined the menus of the top 10 quick service restaurants to find the items that were the highest in calories, carbohydrates, sodium and saturated fat. Here's what they found:

Will Open Letter to McDonald's Bite Into Profits?

McDonald's got a letter from 550 health experts Wednesday accusing the fast food giant of ignoring the impact its products -- and its marketing -- have on America's children. It's not the first such criticism of McDonald's, but so far, the attacks don't appear to have hurt its sales.

What a Wild Year It Was
for Health Care

Led by the health insurance reform law, a flurry of drug and food recalls, key medical breakthroughs and plenty of layoffs and lawsuits, 2010 proved to be an exciting -- if not always positive -- year. Here's our list of the year's biggest health stories.

Vivus Shares Rally on Hopes Obesity Drug Will Gain Approval Next Year

Vivus shares are soaring this morning, even though the U.S. Food and Drug Administration rejected the drugmaker's obesity drug Qnexa yesterday. Investors are hoping that the FDA's rejection, which includes a request for more safety data -- not another clinical trial -- will lead to approval next year.

Abbott Pulls Weight Loss Drug Meridia from Market

Drug and medical-device maker Abbott Laboratories announced Friday that it will voluntarily withdraw its controversial obesity drug Meridia, (sibutramine) from the U.S. market at the request of the FDA, due to concerns it increases the risk of heart attacks and strokes.

New York Wants to Ban Sugary Drinks from Food Stamp Purchases

Mayor Michael Bloomberg sought permission from the federal government to bar New York City%u2019s 1.7 million food stamp recipients from using them to buy sugary drinks such as sodas. Bloomberg, a staunch advocate of anti-obesity measures, sent the request to the United States Department of Agriculture, The New York Times reported.

FDA Panel Votes Against Arena's Diet Drug

Another diet drug, Arena Pharmaceuticals's Iorcaserin, appears to be in danger after a U.S. Food and Drug Administration advisory panel voted to reject it Thursday.

Daily Blogwatch: Are All Hedge Funds Scams?

Among Tuesday's top stories for investors: How do dividend-paying stocks stack up against non-dividend-paying stocks? Is Facebook making it easier for stalkers? Are all hedge funds scams?

Orexigen Shares Soar on Partnership Deal With Takeda

Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.

'Fructose-Slurping' Cancer Could Sour the Soda Business

Soda and processed-food makers insist that all sugars are the same. Yet with studies linking high fructose corn syrup to obesity, diabetes and, most recently, pancreatic cancer, big brands are quietly backing away from using the corn-based sweetener.

Krispy Kreme doughnut burgers?

Is anyone concerned about America's obesity epidemic? Clearly, not the Hoosier family, who have invented the obviously titled "Krispy Kreme...

10 Worst Places to Live

You don't need the U.S. Misery Index to tell you that things are bad in the U.S. Unemployment is near or at all-time highs in many parts of the...

Vivus Hammered After FDA Panel's 'No' Vote

Pharmaceutical company Vivus is getting hammered in premarket trading, sinking more than 50% to around $5.32 in the wake of Thursday's vote by an FDA advisory panel against approving its weight-loss drug, Qnexa, based on safety concerns.

FDA Panel Rejects Weight-Loss Drug Qnexa

Pharmaceutical company Vivus and investors waited anxiously Thursday for the vote of an FDA advisory panel on the weight-loss drug Qnexa. The verdict is in, and by a vote of 9 to 7, panelists didn't support approving the drug as an obesity treatment.

Weight-Loss-Drug Maker Vivus Soars on FDA Review

An expert panel will review Vivus' potential blockbuster drug Qnexa on Thursday, with the FDA making a decision in October. The FDA acknowledges the drug's effectiveness in cutting weight, but it will certainly draw scrutiny over its side effects.

Four Trends That Will Dramatically Change China

The financial media's coverage of China tends to focus on trade-related topics, but China is undergoing deep cultural shifts that will dramatically alter its economic landscape. These four long-term trends could drastically change China -- and its relationship with the world.